Cystic Fibrosis James Lind Alliance Priority Setting Partnership PROTOCOL [updated 13 July 2016]

QR Code

Cystic Fibrosis James Lind Alliance Priority Setting Partnership PROTOCOL [updated 13 July 2016]

The purpose of this protocol is to set out the aims, objectives and commitments of the Cystic Fibrosis Priority Setting Partnership (PSP) and the basic roles and responsibilities of the partners therein.

Bibliographic Details
Main Authors:	Smyth, Alan R., Rowbotham, Nicola J., McPhee, Margaret, Smith, Sherie
Format:	Other
Published:	N/A 2016
Online Access:	https://eprints.nottingham.ac.uk/35223/

Similar Items

Cystic Fibrosis James Lind Alliance Priority Setting Partnership PROTOCOL [5 February 2016]
by: Smyth, Alan R., et al.
Published: (2016)

A systematic review to identify how the current clinical trials landscape reflects the James Lind Alliance top 10 research priorities for cystic fibrosis
by: Kalaitzis, I.S., et al.
Published: (2018)

Working with the patient and clinical community to deliver clinical research in cystic fibrosis. James Lind CF Phase II
by: Smith, S.J., et al.
Published: (2018)

Identifying priority areas for research into the diagnosis, treatment and prevention of cellulitis (erysipelas): results of a James Lind Alliance Priority Setting Partnership
by: Thomas, K.S., et al.
Published: (2017)

Identifying research priorities for digital technology in mental healthcare: results of the James Lind Alliance Priority Setting Partnership
by: Hollis, Chris, et al.
Published: (2018)

Priorities for research in miscarriage: a priority setting partnership between people affected by miscarriage and professionals, following the James Lind Alliance methodology
by: Prior, Matthew, et al.
Published: (2017)

The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and health care providers
by: Rowbotham, Nicola J., et al.
Published: (2017)

Cystic fibrosis microbiology: advances in antimicrobial therapy
by: Waters, Valerie, et al.
Published: (2015)

Prophylactic anti-staphylococcal antibiotics for cystic fibrosis
by: Smyth, Alan R., et al.
Published: (2014)

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis
by: Floto, R. Andres, et al.
Published: (2016)

Delayed publications of clinical trials in cystic fibrosis
by: Hurley, M.N., et al.
Published: (2011)

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
by: Langton Hewer, Simon C., et al.
Published: (2014)

Airway infection and Pseudomonas aeruginosa in bronchiectasis (cystic fibrosis and non-cystic fibrosis bronchiectasis)
by: Webb, Karmel
Published: (2022)

Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis
by: Hurley, M.N., et al.
Published: (2012)

Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis
by: Smyth, Alan R.
Published: (2015)

Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis
by: Smyth, Alan R., et al.
Published: (2014)

Networks, partnerships and alliances
by: Butler, Bella
Published: (2011)

Networks, Partnerships and Alliances
by: Butler, Bella
Published: (2013)

Perceptions of Population Cystic Fibrosis Prenatal and Preconception Carrier Screening Among Individuals with Cystic Fibrosis and Their Family Members
by: Maxwell, Susannah, et al.
Published: (2011)

Prescribing practices for intravenous aminoglycosides in UK cystic fibrosis clinics: a questionnaire survey
by: Smyth, Alan R., et al.
Published: (2014)

Early respiratory bacterial detection and anti-staphylococcal antibiotic prophylaxis in young children with cystic fibrosis
by: Hurley, Matthew, et al.
Published: (2017)

Multiple-breath washout as a lung function test in cystic fibrosis: A cystic fibrosis foundation workshop report
by: Subbarao, P., et al.
Published: (2015)

Glutamine supplementation in cystic fibrosis: a randomized placebo-controlled trial
by: Forrester, Doug L., et al.
Published: (2015)

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis
by: Hurley, M.N., et al.
Published: (2012)

European Cystic Fibrosis Society standards of care: best practice guidelines
by: Smyth, Alan R., et al.
Published: (2014)

Prevention of treatment related adverse effects in cystic fibrosis
by: Jain, Kamini
Published: (2018)

Mitigating the harm caused by Pseudomonas aeruginosa in Cystic Fibrosis
by: Palser, Sally C.
Published: (2024)

METABOLOMIC RESPONSE OF HEALTHY AND CYSTIC FIBROSIS EPITHELIUM TO RHINOVIRUS
by: Agudelo-Romero, P., et al.
Published: (2019)

Identifying peroxidases and their oxidants in the early pathology of cystic fibrosis.
by: Thomson, E., et al.
Published: (2010)

POLYMICROBIAL INFECTION AND NEUTROPHILIC DISEASE IN CYSTIC FIBROSIS AIRWAYS
by: Laucirica, D.R., et al.
Published: (2019)

Respiratory viral infections in Western Australians with cystic fibrosis
by: Brestovac, Brian, et al.
Published: (2020)

Cost-Effectiveness of Carrier Screening for Cystic Fibrosis in Australia
by: Norman, Richard, et al.
Published: (2012)

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis
by: Hurley, M., et al.
Published: (2015)

Understanding chronic inflammatory diseases in the human lung: the cystic fibrosis and idiopathic pulmonary fibrosis paradigms
by: Liu, Yi-Chia
Published: (2014)

Pseudomonas aeruginosa quorum sensing molecules correlate with clinical status in cystic fibrosis
by: Barr, Helen L., et al.
Published: (2015)

Measures of body habitus are associated with lung function in adults with cystic fibrosis: a population-based study
by: Forrester, Doug L., et al.
Published: (2013)

sTREM-1 is elevated in cystic fibrosis and correlates with proteases
by: Forrester, D.L., et al.
Published: (2017)

Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer
by: Gini, A., et al.
Published: (2018)

Association of Antibiotics, Airway Microbiome and Inflammation in Infants with Cystic Fibrosis.
by: Pittman, J., et al.
Published: (2017)

Infection, inflammation,and lung function decline in infants with cystic fibrosis
by: Pillarisetti, N., et al.
Published: (2011)